LifeStance Health Group, Inc. (LFST) shares surged 10.00% in pre-market trading on Thursday following the release of its second-quarter 2025 financial results and third-quarter outlook. The company's performance exceeded analyst expectations in several key areas, demonstrating resilience and growth potential in the healthcare sector.
LifeStance reported a narrower-than-expected net loss of $3.8 million for Q2, significantly beating the IBES estimate of a $9.87 million loss. The company's adjusted EBITDA came in at $34 million, surpassing the expected $31.1 million. Revenue for the quarter reached $345.3 million, slightly above the anticipated $345.2 million, indicating steady growth and market demand for LifeStance's services.
Looking ahead, LifeStance provided an optimistic outlook for the third quarter of 2025. The company forecasts Q3 revenue between $345 million and $365 million, with adjusted EBITDA projected to range from $33 million to $39 million. This positive guidance suggests continued momentum and operational efficiency, likely contributing to investor enthusiasm and the subsequent pre-market stock rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.